Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 8401–8450 of 35185
the following six (6) former directors of CBC were appointed to serve as directors on the Company’s board of directors (the “Board”), effective as of the Effective Time: Steven E. Shelton, Stephen A. Cortese, Andrew J. Armanino, Jr., Kevin J. Cullen, Rochelle G. Klein and Frank L. Muller (the “New Directors”).
Irwin Golds, Kaveh Varjavand and Anita Wolman (the “Retiring Directors”) retired from the SCB Board effective at the Effective Time.
the following six (6) former directors of CBC were appointed to serve as directors on the Company’s board of directors (the “Board”), effective as of the Effective Time: Steven E. Shelton, Stephen A. Cortese, Andrew J. Armanino, Jr., Kevin J. Cullen, Rochelle G. Klein and Frank L. Muller (the “New Directors”).
Irwin Golds, Kaveh Varjavand and Anita Wolman (the “Retiring Directors”) retired from the SCB Board effective at the Effective Time.
the following six (6) former directors of CBC were appointed to serve as directors on the Company’s board of directors (the “Board”), effective as of the Effective Time: Steven E. Shelton, Stephen A. Cortese, Andrew J. Armanino, Jr., Kevin J. Cullen, Rochelle G. Klein and Frank L. Muller (the “New Directors”).
the following six (6) former directors of CBC were appointed to serve as directors on the Company’s board of directors (the “Board”), effective as of the Effective Time: Steven E. Shelton, Stephen A. Cortese, Andrew J. Armanino, Jr., Kevin J. Cullen, Rochelle G. Klein and Frank L. Muller (the “New Directors”).
Irwin Golds, Kaveh Varjavand and Anita Wolman (the “Retiring Directors”) retired from the SCB Board effective at the Effective Time.
Effective upon the closing of the Business Combination, each of Chung-Yi Sun, Cheng-Nan Wu, Lin Bao, Jung-Te Chang and Grace F. L. Peng ceased serving as a director of the Company, and each of Chung-Yi Sun and Cheng-Nan Wu ceased serving as an executive officer of the Company.
Effective upon the closing of the Business Combination, each of Chung-Yi Sun, Cheng-Nan Wu, Lin Bao, Jung-Te Chang and Grace F. L. Peng ceased serving as a director of the Company, and each of Chung-Yi Sun and Cheng-Nan Wu ceased serving as an executive officer of the Company.
Effective upon the closing of the Business Combination, each of Chung-Yi Sun, Cheng-Nan Wu, Lin Bao, Jung-Te Chang and Grace F. L. Peng ceased serving as a director of the Company, and each of Chung-Yi Sun and Cheng-Nan Wu ceased serving as an executive officer of the Company.
Effective upon the closing of the Business Combination, each of Chung-Yi Sun, Cheng-Nan Wu, Lin Bao, Jung-Te Chang and Grace F. L. Peng ceased serving as a director of the Company, and each of Chung-Yi Sun and Cheng-Nan Wu ceased serving as an executive officer of the Company.
Effective upon the closing of the Business Combination, each of Chung-Yi Sun, Cheng-Nan Wu, Lin Bao, Jung-Te Chang and Grace F. L. Peng ceased serving as a director of the Company, and each of Chung-Yi Sun and Cheng-Nan Wu ceased serving as an executive officer of the Company.
On July 29, 2024, Shimon Rapp and Andrew Sycoff resigned from the board of directors.
On July 29, 2024, Shimon Rapp and Andrew Sycoff resigned from the board of directors.
on July 25, 2024, the Company’s Board appointed Shankar Hariharan and Narasimhan Mani to the Board.
on July 25, 2024, the Company’s Board appointed Shankar Hariharan and Narasimhan Mani to the Board.
On July 26, 2024, Bradley (“Brad”) Weston provided notice of his decision to resign from the Board of Directors (the “Board”) of Vera Bradley, Inc. (the “Company”) effective August 30, 2024.
On July 30, 2024, Joel V. Staff notified Kinder Morgan, Inc. (“KMI”) that he will retire from KMI’s Board of Directors effective August 1, 2024.
Nazim Cetin and Andreas Wimmer were appointed as directors on the Board, as the Investor Designees, to serve until their respective terms and until their successors are elected and qualified, and the size of the Board was fixed at eight directors.
Nazim Cetin and Andreas Wimmer were appointed as directors on the Board, as the Investor Designees, to serve until their respective terms and until their successors are elected and qualified, and the size of the Board was fixed at eight directors.
On July 25, 2024, the Company received written notice from Solomon Adote of his resignation as a member of the Board of Directors
On July 25, 2024, the Company received written notice from Dr. Emmanuel Esaka of his resignation as a member of the Board of Directors
Ms. Kathleen M. Pawlus, age 64, was appointed a member of the Board to serve as a director effective August 15, 2024, with a term expiring at the Company's 2025 Annual Meeting of Shareholders.
Peter M. Fasolo, Ph.D., and Joseph J. Wolk each informed Kenvue Inc. (the "Company") and its Board of Directors (the "Board") of their decision to resign from the Board, effective as of December 1, 2024.
Mr. Kirk L. Perry, age 57, was appointed a member of the Board to serve as a director effective immediately after the resignations of Messrs. Fasolo and Wolk on December 1, 2024, with a term expiring at the 2025 Annual Meeting.
Peter M. Fasolo, Ph.D., and Joseph J. Wolk each informed Kenvue Inc. (the "Company") and its Board of Directors (the "Board") of their decision to resign from the Board, effective as of December 1, 2024.
appointed David C. Habiger, to be a director of the Company, to hold office until the next annual meeting of stockholders, effective July 30, 2024.
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
each of Michael Browning (Chairman of the Board), Eric Spiegel and Nina Jensen ceased to be a director of PERAC
each of Michael Browning (Chairman of the Board), Eric Spiegel and Nina Jensen ceased to be a director of PERAC
On July 26, 2024, the Board of Directors (the “Board”) of Eagle Bancorp, Inc. (the “Company”), the parent company of EagleBank (the “Bank”), and the Board of Directors of the Bank, upon the recommendation of the Governance and Nominating Committee of the Board, elected Louis P. “Pete” Mathews Jr. as a director of the Company and of the Bank, effective immediately.
Stephen Goodman ceased to act as a director of the Company on July 26, 2024.
On July 26, 2024, the Board of Directors (the “Board”) of SpringWorks Therapeutics, Inc. (the “Company”), appointed Martin Mackay as a member of the Board, effective July 29, 2024.
On July 29, 2024, the Board of Directors (the “ Board ”) of Orchestra BioMed Holdings, Inc. (the “ Company ”) appointed John Mack to serve as a Class I director, effective immediately
On July 27, 2024, the board of directors (the “ Board ”) of Churchill Capital Corp IX (the “ Company ”) appointed William Sherman as a director and as a member of the audit committee and the compensation committee of the Board, effective as of July 30, 2024.
On July 24, 2024, Todd Penegor advised Perrigo Company plc (“Perrigo” or the “Company”) that he would be resigning from the Company’s board of directors (the “Board”), effective July 31, 2024.
On July 26, 2024, Joe Aric Peters notified Butler National Corporation (the “Company”) that he resigned as a member of the Company’s Board of Directors (the “Board”) effective immediately.
On July 25, 2024, M2i Global, Inc. (“the Company”) appointed Lieutenant General (Ret) Jeffrey W. Talley, a seasoned international business executive, to its Board of Directors, as a director.
As previously disclosed, Peter Gross, a member of the Board of Directors (the “Board”) of Polar Power, Inc. (the “Company”), resigned as a member of the Board of Directors of the Company.
The remaining members of the Board appointed and ratified Mr. Michael G. Field, to serve as a member of the Board, effective as of July 25, 2024, and to assume the position of Mr. Gross as a member of the audit committee, chair of the compensation committee and chair of the nominating and corporate governance committee of the Board.
On July 25, 2024, Steve Gorlin notified the Board of Directors (the “Board”) of BioVie Inc. (the “Company”) of his intention to resign as a director of the Company, effective immediately.
On July 26, 2024, each of Andrew H. Tisch and Jonathan M. Tisch informed the Corporation that they will retire from their positions as directors, including as Co-Chairmen of the Board of Directors, of the Corporation, effective December 31, 2024.
On July 26, 2024, the Board of Directors elected Alexander H. Tisch and Benjamin J. Tisch as directors of the Corporation and appointed them as members of the Executive Committee of the Board of Directors, in each case effective January 1, 2025.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.